Source: Pharmacy Times articles
Seven new agents have received FDA approval since October 2022.
Read More
Recent Content
- High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
- CAR-T cell therapy in Multiple Myeloma: current status and future challenges
- Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
- Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
- Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
- A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
- Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
- A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
- Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
- A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma